Logo
  • Search
  • Subscribe
  • Login
  • News
  • Business
  • Opinion
  • Archive
  • Jobs Market
  • About DT
  • Contact
  • Search
  • Subscribe
  • Login

Evaluation: Big Pharma shies away from CEPI due to equitable access requirements

News December 19, 2022 / By: Ann Danaiya Usher

The Oslo-based vaccine initiative CEPI has over a few short years grown into a “credible and prominent” global actor but risks spreading itself too thin as it expands its mandate to include vaccine manufacturing, a recent evaluation concludes. CEPI also faces a dilemma: profit-driven Big Pharma has largely refused to engage with CEPI because of equitable access conditions attached to grants.

cepi illustration.jpg

Photo by CEPI

If you are new to Development Today and would like to continue reading this article, send us a mail at subscribers@devtoday.no, including your name, title, organisation, and email contact, and you will receive a free Guest Pass, along with weekly updates.

Log in or subscribe

Tags:

Global health
  • Home
  • Archive
  • 2022
  • DT 9-10 / 2022
  • Evaluation: Big Pharma shies away from CEPI due to equitable access requirements

Development Today AS
Box 140
1371 Asker
Norway
Tel: +47 66902660
E-mail: devtoday@devtoday.no

  • News
  • Business
  • Opinion
  • Archive
  • About DT
  • Privacy and Cookie policy
  • Contact
  • Log in
  • Subscribe

Design and development: Snapper Net Solutions